Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, SAR, China.
Nephron Clin Pract. 2010;116(4):c300-6. doi: 10.1159/000318793. Epub 2010 Jul 16.
Peritoneal dialysis (PD) and hemodialysis (HD) are often regarded as equivalent choices of renal replacement therapy. However, little is known about the outcome of patients who failed PD and converted to long-term HD.
We reviewed 197 patients who received long-term HD after failed PD in a University hospital from 1994 to 2008 (the PD-first group) and 140 patients who received long-term HD as their initial therapy during that period (the primary-HD group). Their survival rates are compared.
The two groups are highly comparable in terms of baseline demographic data. The PD-first group required more temporary dialysis catheters than the primary-HD group (3.1 ± 3.4 vs. 1.5 ± 1.8, p < 0.0001). At 5 years, the actuarial survival of the PD-first group was significantly lower than that of the primary-HD group (39.9 vs. 59.7%, p < 0.0001), while technique survival was similar (30.4 vs. 30.1%, p = 0.7). When analysis on actuarial survival was performed for patients who survived the first 12 months on HD, the 5-year survival became similar (65.2 vs. 68.8%, p = 0.5). During the first 12 months on HD, independent predictors of actuarial survival of the PD-first group were duration of PD, Charlson's comorbidity score, type of permanent access and serum albumin before conversion; after 12 months, independent predictors of actuarial survival were Charlson's comorbidity score, total Kt/V, residual renal function, fat-free edema-free body mass before conversion and baseline peritoneal transport.
Patients who were converted to long-term HD after failed PD had a higher mortality than patients who used HD as the primary modality of renal replacement therapy. The excessive mortality, however, was limited to the first 12 months after conversion, and the technique survival was similar between the two groups. Vascular access is a common problem in patients who failed PD.
腹膜透析(PD)和血液透析(HD)通常被视为肾脏替代治疗的等效选择。然而,对于 PD 失败后转为长期 HD 的患者的结局知之甚少。
我们回顾了 1994 年至 2008 年期间在一家大学医院接受 PD 失败后转为长期 HD 的 197 例患者(PD 组)和同期接受长期 HD 作为初始治疗的 140 例患者(原 HD 组)。比较两组患者的生存率。
两组患者在基线人口统计学数据方面高度可比。PD 组需要的临时透析导管多于原 HD 组(3.1±3.4 与 1.5±1.8,p<0.0001)。5 年时,PD 组的生存率明显低于原 HD 组(39.9%与 59.7%,p<0.0001),而技术生存率相似(30.4%与 30.1%,p=0.7)。对 HD 治疗 12 个月后存活的患者进行生存率分析,5 年生存率变得相似(65.2%与 68.8%,p=0.5)。在 HD 治疗的前 12 个月,PD 组患者生存率的独立预测因素是 PD 持续时间、Charlson 合并症评分、永久性通路类型和转换前血清白蛋白;12 个月后,生存率的独立预测因素是 Charlson 合并症评分、总 Kt/V、残余肾功能、转换前去脂去水肿体质量和基线腹膜转运。
PD 失败后转为长期 HD 的患者死亡率高于初始采用 HD 作为肾脏替代治疗主要方式的患者。然而,这种过高的死亡率仅限于转换后的前 12 个月,两组之间的技术生存率相似。PD 失败患者常见的血管通路问题。